[MVA-vaccine in primovaccination against XXXX after the age of three (author's transl)].

@entity1 @entity14333 @entity6831
These are the results of 417 primary vaccinations against @entity14333 with MVA, an attenuated vaccine. All of the @entity1 were over three years old. In Europe, this group has an increased risk of @entity6831 . The intracutaneous inoculation produced a light local infiltration and only 11.7% showed a light generalized reaction. In order to attain a reliable immunity, a second inoculation was performed one week later, epicutaneously with Elstree-vaccine. The local reaction was in general that of a normal revaccination, and 79.4% of our @entity1 had neither fever nor general symptoms. Among the others no one became seriously ill. We did not observe any complications specific for a @entity14333 vaccination. In comparison to the other vaccination methods currently used, the MVA "Two-step"-vaccination is probably the safest. Its risk of a @entity6831 is supposed to be lower according to animal experiments and theoretical considerations. This hypothesis has been confirmed meanwhile by the results of several thousand vaccinations in the already mentioned age-group.
